A Phosphoramidate Strategy Enables Membrane Permeability of a Non-nucleotide Inhibitor of the Prolyl Isomerase Pin1

Daniel M.C. Schwarz; Sarah K. Williams; Maxwell Dillenburg; Carston R. Wagner; Jason E. Gestwicki

doi:10.1021/acsmedchemlett.0c00170

A Phosphoramidate Strategy Enables Membrane Permeability of a Non-nucleotide Inhibitor of the Prolyl Isomerase Pin1

Daniel M.C. Schwarz, Sarah K. Williams, Maxwell Dillenburg, Carston R. Wagner, Jason E. Gestwicki

Medicinal Chemistry

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

The membrane permeability of nucleotide-based drugs, such as sofosbuvir (Sovaldi), requires installation of phosphate-caging groups. One strategy, termed "ProTide", masks the anionic phosphate through an N-linked amino ester and an O-linked aromatic phospho-ester, such that release of the active drug requires consecutive enzymatic liberation by an esterase and then a phosphoramidase, such as Hint1. Because Hint1 is known to be selective for nucleotides, it was not clear if the ProTide approach could be deployed for non-nucleotides. Here, we demonstrate that caging of a phosphate-containing inhibitor of the prolyl isomerase Pin1 increases its permeability. Moreover, this compound was processed by both esterase and phosphoramidase activity, releasing the active molecule to bind and inhibit Pin1 in cells. Thus, Hint1 appears to recognize a broader set of substrates than previously appreciated. It seems possible that other potent, but impermeable, phosphate-containing inhibitors might likewise benefit from this approach.

Original language	English (US)
Pages (from-to)	1704-1710
Number of pages	7
Journal	ACS Medicinal Chemistry Letters
Volume	11
Issue number	9
DOIs	https://doi.org/10.1021/acsmedchemlett.0c00170
State	Published - Sep 10 2020

Bibliographical note

Funding Information:
This work was supported by a predoctoral fellowship (1 F31 CA232325-01A1 to D.M.C.S.) and training program Cancer Cell Map Initiative (U54CA209891 to D.M.C.S.) and grants from the University of California Drug Discovery Consortium (UCDDC; to J.E.G.), the UCSF InVent Fund (to J.E.G.), and the University of Minnesota Foundation (to C.R.W.). The authors thank Bryan Dunyak for early contributions to the project.

Publisher Copyright:
Copyright © 2020 American Chemical Society.

Keywords

Hint1
PPIase
ProTide
oncology
phosphate-containing
pro-drug

Access

10.1021/acsmedchemlett.0c00170

OpenUrl availability

Full text

Cite this

@article{0a63b6f580874ee7b5b1954893dd04ab,

title = "A Phosphoramidate Strategy Enables Membrane Permeability of a Non-nucleotide Inhibitor of the Prolyl Isomerase Pin1",

abstract = "The membrane permeability of nucleotide-based drugs, such as sofosbuvir (Sovaldi), requires installation of phosphate-caging groups. One strategy, termed {"}ProTide{"}, masks the anionic phosphate through an N-linked amino ester and an O-linked aromatic phospho-ester, such that release of the active drug requires consecutive enzymatic liberation by an esterase and then a phosphoramidase, such as Hint1. Because Hint1 is known to be selective for nucleotides, it was not clear if the ProTide approach could be deployed for non-nucleotides. Here, we demonstrate that caging of a phosphate-containing inhibitor of the prolyl isomerase Pin1 increases its permeability. Moreover, this compound was processed by both esterase and phosphoramidase activity, releasing the active molecule to bind and inhibit Pin1 in cells. Thus, Hint1 appears to recognize a broader set of substrates than previously appreciated. It seems possible that other potent, but impermeable, phosphate-containing inhibitors might likewise benefit from this approach.",

keywords = "Hint1, PPIase, ProTide, oncology, phosphate-containing, pro-drug",

author = "Schwarz, {Daniel M.C.} and Williams, {Sarah K.} and Maxwell Dillenburg and Wagner, {Carston R.} and Gestwicki, {Jason E.}",

note = "Funding Information: This work was supported by a predoctoral fellowship (1 F31 CA232325-01A1 to D.M.C.S.) and training program Cancer Cell Map Initiative (U54CA209891 to D.M.C.S.) and grants from the University of California Drug Discovery Consortium (UCDDC; to J.E.G.), the UCSF InVent Fund (to J.E.G.), and the University of Minnesota Foundation (to C.R.W.). The authors thank Bryan Dunyak for early contributions to the project. Publisher Copyright: Copyright {\textcopyright} 2020 American Chemical Society.",

year = "2020",

month = sep,

day = "10",

doi = "10.1021/acsmedchemlett.0c00170",

language = "English (US)",

volume = "11",

pages = "1704--1710",

journal = "ACS Medicinal Chemistry Letters",

issn = "1948-5875",

publisher = "American Chemical Society",

number = "9",

}

TY - JOUR

T1 - A Phosphoramidate Strategy Enables Membrane Permeability of a Non-nucleotide Inhibitor of the Prolyl Isomerase Pin1

AU - Schwarz, Daniel M.C.

AU - Williams, Sarah K.

AU - Dillenburg, Maxwell

AU - Wagner, Carston R.

AU - Gestwicki, Jason E.

N1 - Funding Information: This work was supported by a predoctoral fellowship (1 F31 CA232325-01A1 to D.M.C.S.) and training program Cancer Cell Map Initiative (U54CA209891 to D.M.C.S.) and grants from the University of California Drug Discovery Consortium (UCDDC; to J.E.G.), the UCSF InVent Fund (to J.E.G.), and the University of Minnesota Foundation (to C.R.W.). The authors thank Bryan Dunyak for early contributions to the project. Publisher Copyright: Copyright © 2020 American Chemical Society.

PY - 2020/9/10

Y1 - 2020/9/10

N2 - The membrane permeability of nucleotide-based drugs, such as sofosbuvir (Sovaldi), requires installation of phosphate-caging groups. One strategy, termed "ProTide", masks the anionic phosphate through an N-linked amino ester and an O-linked aromatic phospho-ester, such that release of the active drug requires consecutive enzymatic liberation by an esterase and then a phosphoramidase, such as Hint1. Because Hint1 is known to be selective for nucleotides, it was not clear if the ProTide approach could be deployed for non-nucleotides. Here, we demonstrate that caging of a phosphate-containing inhibitor of the prolyl isomerase Pin1 increases its permeability. Moreover, this compound was processed by both esterase and phosphoramidase activity, releasing the active molecule to bind and inhibit Pin1 in cells. Thus, Hint1 appears to recognize a broader set of substrates than previously appreciated. It seems possible that other potent, but impermeable, phosphate-containing inhibitors might likewise benefit from this approach.

AB - The membrane permeability of nucleotide-based drugs, such as sofosbuvir (Sovaldi), requires installation of phosphate-caging groups. One strategy, termed "ProTide", masks the anionic phosphate through an N-linked amino ester and an O-linked aromatic phospho-ester, such that release of the active drug requires consecutive enzymatic liberation by an esterase and then a phosphoramidase, such as Hint1. Because Hint1 is known to be selective for nucleotides, it was not clear if the ProTide approach could be deployed for non-nucleotides. Here, we demonstrate that caging of a phosphate-containing inhibitor of the prolyl isomerase Pin1 increases its permeability. Moreover, this compound was processed by both esterase and phosphoramidase activity, releasing the active molecule to bind and inhibit Pin1 in cells. Thus, Hint1 appears to recognize a broader set of substrates than previously appreciated. It seems possible that other potent, but impermeable, phosphate-containing inhibitors might likewise benefit from this approach.

KW - Hint1

KW - PPIase

KW - ProTide

KW - oncology

KW - phosphate-containing

KW - pro-drug

UR - http://www.scopus.com/inward/record.url?scp=85089969819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089969819&partnerID=8YFLogxK

U2 - 10.1021/acsmedchemlett.0c00170

DO - 10.1021/acsmedchemlett.0c00170

M3 - Article

C2 - 32944137

AN - SCOPUS:85089969819

SN - 1948-5875

VL - 11

SP - 1704

EP - 1710

JO - ACS Medicinal Chemistry Letters

JF - ACS Medicinal Chemistry Letters

IS - 9

ER -

A Phosphoramidate Strategy Enables Membrane Permeability of a Non-nucleotide Inhibitor of the Prolyl Isomerase Pin1

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this